GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » Gross Profit

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Gross Profit : $0.63 Mil (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals Gross Profit?

China SXT Pharmaceuticals's gross profit for the six months ended in Sep. 2023 was $0.29 Mil. China SXT Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $0.63 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. China SXT Pharmaceuticals's gross profit for the six months ended in Sep. 2023 was $0.29 Mil. China SXT Pharmaceuticals's Revenue for the six months ended in Sep. 2023 was $0.94 Mil. Therefore, China SXT Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2023 was 30.64%.

China SXT Pharmaceuticals had a gross margin of 30.64% for the quarter that ended in Sep. 2023 => Competition eroding margins

During the past 7 years, the highest Gross Margin % of China SXT Pharmaceuticals was 65.77%. The lowest was 21.60%. And the median was 48.45%.

Warning Sign:

China SXT Pharmaceuticals Inc gross margin has been in long-term decline. The average rate of decline per year is -12.9%.


China SXT Pharmaceuticals Gross Profit Historical Data

The historical data trend for China SXT Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Gross Profit Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Profit
Get a 7-Day Free Trial 4.61 2.70 2.84 1.25 0.43

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.93 0.09 0.34 0.29

Competitive Comparison of China SXT Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China SXT Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's Gross Profit falls into.



China SXT Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

China SXT Pharmaceuticals's Gross Profit for the fiscal year that ended in Mar. 2023 is calculated as

Gross Profit (A: Mar. 2023 )=Revenue - Cost of Goods Sold
=1.972 - 1.546
=0.43

China SXT Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2023 is calculated as

Gross Profit (Q: Sep. 2023 )=Revenue - Cost of Goods Sold
=0.94 - 0.652
=0.29

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.63 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

China SXT Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.29 / 0.94
=30.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


China SXT Pharmaceuticals  (NAS:SXTC) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

China SXT Pharmaceuticals had a gross margin of 30.64% for the quarter that ended in Sep. 2023 => Competition eroding margins


China SXT Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.